Practices
Industries
Value-Added Services
Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.
Advancing professional knowledge and offering credits for attorneys, staff and other professionals.
Helping clients respond correctly when a crisis occurs.
Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.
Leveraging law and technology to deliver sound solutions.
Delivering seamless service through partnerships across the globe.
Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.
Industry-leading conferences focused on affordable housing, tax credits, and more.
Providing actionable information to support strategic decision-making.
Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.
Offering a range of investment management and fiduciary services.
Bringing together companies and investors for tomorrow’s new deals.
Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.
Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.
Creating positive impact in our communities through increasing equity, access, and opportunity.
Michael Smith is a partner in Nixon Peabody’s Corporate practice group. Michael has more than 25 years-of-experience advising international and domestic companies on global capital markets and U.S. securities law, cross-border M&A transactions, international fund formation, and Shariah finance.
Michael is licensed to practice law in New York and Ontario, Canada, and has practiced at leading firms in London, New York, and Toronto.
I advise public and private companies in mergers and acquisitions with significant cross-border experience, advising on transactions into and out of the United States, Canada, Europe, the Middle East, North Africa, sub-Saharan Africa, Latin America, and China.
With deep experience across a wide range of industries, including financial services, health care, life sciences, and oil and gas, I have developed a focus in the cannabis space in recent years. Given the massive disruption across the cannabis industry, much of my recent work has involved counseling cannabis companies and investors on distressed Canada-U.S. cross-border transactions.
I have recently advised numerous issuers and underwriters on cross-border offerings of equity, high-yield debt, sovereign debt, and structured debt registered with the U.S. Securities and Exchange Commission (SEC), as well as the Canada-U.S. Multi-Jurisdiction Disclosure System (MJDS). I am well versed in Rule 144A, Regulation D, and Regulation S offerings as well. I also guided United States and non-U.S. companies on their listings with international exchanges, including the New York Stock Exchange (NYSE), the Nasdaq, the London Stock Exchange, the Toronto Stock Exchange, and several other regional exchanges. In addition, I regularly counsel boards, senior management, and private equity firms with respect to corporate governance, deal structuring, and strategy.
Michael joined Nixon Peabody in November 2020. The representative work set forth below may reflect experience from prior firms.
The use of special-purpose acquisition companies (SPACs) by private equity firms to raise assets under management (AUM) on Canadian, U.S., and UK stock exchanges will continue to grow.
I also expect the Middle East will generate more transactional work, especially cross- border financings and projects, due to the normalization of Israeli-Arab commercial relations and the modernization of Saudi Arabia.
This article on the surge in private equity deals includes NP for advising the owners of skin care brand Obagi in its $1.2 billion business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi’s operations in China.
The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.
This article covering a roughly $1.2 billion merger of skin care and beauty brands with a special purpose acquisition company mentions NP for advising the owners of skin care brand Obagi in its business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi's operations in China.
The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.
New York
Ontario (Canada)
England and Wales (non-practising)
Queen's University, Canada, LL.B.
University of Toronto, Trinity College, B.A.
Press Release
Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe